Theme 10: Haematological malignancy

2008 ◽  
pp. 184-184
Keyword(s):  
Haematological Malignancy

Different threshold levels for red blood cell transfusions in patients with haematological malignancy

2009 ◽  
Author(s):  
Rachel Pawson ◽  
Susan Brunskill ◽  
Michael F Murphy ◽  
Carolyn Doree ◽  
Chris Hyde ◽  
...  
Keyword(s):  
Blood Cell ◽  
Red Blood Cell ◽  
Haematological Malignancy ◽  
Threshold Levels ◽  
Red Blood Cell Transfusions

scholarly journals MOLECULAR SUBCLUSTERS OF FOLLICULAR LYMPHOMA: A REPORT FROM THE UK'S HAEMATOLOGICAL MALIGNANCY RESEARCH NETWORK

2021 ◽  
Vol 39 (S2) ◽  
Author(s):  
S. Crouch ◽  
D. Painter ◽  
S. Barrans ◽  
E. Roman ◽  
P. Beer ◽  
...  
Keyword(s):  
Follicular Lymphoma ◽  
Haematological Malignancy ◽  
Research Network

Calculated globulin as a screening tool for hypogammaglobulinaemia or paraproteins in hospitalized patients

2021 ◽  
pp. 000456322198973
Author(s):  
Teng Hoo ◽  
Ee Mun Lim ◽  
Mina John ◽  
Lloyd D’Orsogna ◽  
Andrew McLean-Tooke
Keyword(s):  
Positive Predictive Value ◽  
Predictive Value ◽  
Screening Tool ◽  
Haematological Malignancy ◽  
Laboratory Data ◽  
Liver Function Tests ◽  
Serum Globulin ◽  
Tertiary Hospitals ◽  
Low Sensitivity ◽  
Diagnostic Delays

Background Calculated globulin fraction is derived from the liver function tests by subtracting albumin from the total protein. Since immunoglobulins comprise the largest component of the serum globulin concentration, increased or decreased calculated globulins and may identify patients with hypogammaglobulinaemia or hypergammaglobulinaemia, respectively. Methods A retrospective study of laboratory data over 2.5 years from inpatients at three tertiary hospitals was performed. Patients with paired calculated globulins and immunoglobulin results were identified and clinical details reviewed. The results of serum electrophoresis testing were also assessed where available. Results A total of 4035 patients had paired laboratory data available. A calculated globulin ≤20 g/L (<2nd percentile) had a low sensitivity (5.8%) but good positive predictive value (82.5%) for hypogammaglobulinaemia (IgG ≤5.7 g/L), with a positive predictive value of 37.5% for severe hypogammaglobulinaemia (IgG ≤3 g/L). Paraproteins were identified in 123/291 (42.3%) of patients with increased calculated globulins (≥42 g/L) who also had a serum electrophoresis performed. Significantly elevated calculated globulin ≥50 g/L (>4th percentile) were seen in patients with either liver disease (37%), haematological malignancy (36%), autoimmune disease (13%) or infections (9%). Conclusions Calculated globulin is an inexpensive and easily available test that assists in the identification of hypogammaglobulinaemia or hypergammaglobulinaemia which may prompt further investigation and reduce diagnostic delays.

scholarly journals Neuroimaging of CNS infection in haematological malignancy: important signs and common diagnostic pitfalls

2021 ◽  
Author(s):  
E.A. Lim ◽  
R. Gnanadurai ◽  
J.K. Ruffle ◽  
H. Lee ◽  
R.F. Miller ◽  
...  
Keyword(s):  
Haematological Malignancy ◽  
Cns Infection ◽  
Diagnostic Pitfalls

scholarly journals Conventional myelosuppressive chemotherapy for non-haematological malignancy disrupts the intestinal microbiome

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Lito E. Papanicolas ◽  
Sarah K. Sims ◽  
Steven L. Taylor ◽  
Sophie J. Miller ◽  
Christos S. Karapetis ◽  
...  
Keyword(s):  
Gut Microbiota ◽  
Relative Abundance ◽  
Haematological Malignancy ◽  
Amplicon Sequencing ◽  
Intestinal Microbiome ◽  
Rrna Gene ◽  
Conventional Chemotherapy ◽  
Myelosuppressive Chemotherapy ◽  
Gram Positive Bacteria ◽  
Faecal Samples

Abstract Background The gut microbiota influences many aspects of host physiology, including immune regulation, and is predictive of outcomes in cancer patients. However, whether conventional myelosuppressive chemotherapy affects the gut microbiota in humans with non-haematological malignancy, independent of antibiotic exposure, is unknown. Methods Faecal samples from 19 participants with non-haematological malignancy, who were receiving conventional chemotherapy regimens but not antibiotics, were examined prior to chemotherapy, 7–12 days after chemotherapy, and at the end of the first cycle of treatment. Gut microbiota diversity and composition was determined by 16S rRNA gene amplicon sequencing. Results Compared to pre-chemotherapy samples, samples collected 7–12 days following chemotherapy exhibited increased richness (mean 120 observed species ± SD 38 vs 134 ± 40; p = 0.007) and diversity (Shannon diversity: mean 6.4 ± 0.43 vs 6.6 ± 0.41; p = 0.02). Composition was significantly altered, with a significant decrease in the relative abundance of gram-positive bacteria in the phylum Firmicutes (pre-chemotherapy median relative abundance [IQR] 0.78 [0.11] vs 0.75 [0.11]; p = 0.003), and an increase in the relative abundance of gram-negative bacteria (Bacteroidetes: median [IQR] 0.16 [0.13] vs 0.21 [0.13]; p = 0.01 and Proteobacteria: 0.015 [0.018] vs 0.03 [0.03]; p = 0.02). Differences in microbiota characteristics from baseline were no longer significant at the end of the chemotherapy cycle. Conclusions Conventional chemotherapy results in significant changes in gut microbiota characteristics during the period of predicted myelosuppression post-chemotherapy. Further study is indicated to link microbiome changes during chemotherapy to clinical outcomes.

Sign in / Sign up

Export Citation Format

Share Document